Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

CAPR scientists continued to work towards establishing novel preclinical modelling tools extensively vetted for and valuable in early-stage drug development. For its diverse contribution to the CCR-funded resource base in preclinical cancer modelling experimental platforms, CAPR Program have received a Federal Technology Transfer Award for the development of novel PDX models for small cell lung cancer (SCLC). This set of PDX from 20 different patients with relapsed SCLC after chemotherapy or chemo-immunotherapy is a valuable resource for CCR investigators and outside collaborators to find novel and much needed therapies for recalcitrant SCLC. A manuscript showing that chromatin accessibility profiling in PDX models identifies a predictive stem-like subtype of SCLC was submitted. CAPR also developed and characterized 3 novel PDX models for anaplastic, metastatic Kaposi sarcoma that grow aggressively in mice. These are the first PDX models for this disease and have been filed in an EIR, as distribution will be of great value to the KS investigator community. Additionally, in collaboration with CCR's Mouse Cancer Genetics Program, CAPR scientists expanded their model repertoire, adding several GEM models that facilitate studies in clonal hematopoiesis and myeloid leukemia development. This model meets the need for more relevant models of human myeloid malignancies to allow for the development and testing of novel therapeutics. As a part of model quality validation, several pharmacokinetic and drug efficacy studies have been completed with several novel formulations currently considered for clinical translation.